|Bid||125.82 x 1100|
|Ask||130.80 x 1800|
|Day's Range||126.64 - 128.98|
|52 Week Range||74.51 - 130.75|
|Beta (3Y Monthly)||0.46|
|PE Ratio (TTM)||40.99|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||2.58 (2.01%)|
|1y Target Est||122.00|
Biotech giant Biogen stock cratered 28% on Thursday, after the company announced that it would be pulling the plug on its ate-stage trial of its Alzeimer’s drug aducanumab.
The best pharmaceutical stocks to buy have commonalities: Strong Composite Ratings and Relative Strength Ratings.
Goldman Sachs expects the Fed;s newly dovish policy to lead to a gradual increase in inflation, favoring high-margin stocks with “pricing power.”
While plenty of investors flocked to health care in the second half of 2018—making Merck (MRK) the Dow Jones Industrial Average’s best performer for the year—Eli Lilly still managed to stand out from the crowd. The shares got a boost from upbeat drug trial data, dividend increases, and robust earnings and guidance. (Barron’shighlighted the stock’s attractive prospects last summer.) Although the stock sold off after its fourth-quarter earnings and full-year guidance in February, and on news it would lower the cost of its insulin treatment earlier this month, the shares are still up 65% in the trailing 12-month period. On Wednesday, UBS’s Navin Jacob reinstated coverage of Eli Lilly with a Buy rating and raised his price target by $9 to $140.
PLYMOUTH MEETING, Pa. and INDIANAPOLIS , March 20, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network ® ( NCCN ® ) Oncology Research Program ( ORP ) and Eli Lilly and Company (NYSE: LLY) today ...
How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts have set Eli Lilly and Company’s (LLY) 12-month consensus target price at $122, 2.59% lower than
Eli Lilly and Co NYSE:LLYView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining Bearish sentimentShort interest | PositiveShort interest is moderate for LLY with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 15. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding LLY is favorable, with net inflows of $17.92 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. LLY credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Shares of global pharma giant Eli Lilly (NYSE:LLY) have performed incredibly well over the past decade, rising more than 350% as the market gained 300%. But, the LLY stock rally has kicked into overdrive during the past year. Shares are up more than 60% while the Dow Jones Industrial Average is pretty much flat over that same stretch.This big rally against the backdrop of a flat market has some investors concerned. Are these gains sustainable? Or is LLY stock out over its skis here?As we head into the close of the first quarter, the numbers support the bull thesis. Eli Lilly stock is a powered by healthy tailwinds from pharma product portfolio expansion and increased global healthcare spend. Rounding out this story are steady positive revenue growth, margin expansion and healthy profit growth. Assuming this persists -- and it should -- LLY stock has upside to prices above $135 in 2019.InvestorPlace - Stock Market News, Stock Advice & Trading TipsEli Lilly stock currently trades around $125, so the shares should reasonably head 8% higher into the end of the year. Coupled with a 2%+ yield, LLY stock should produce about 10% return from here over the next 12 months. That is fairly good return from of a low-risk, stable-growth company like Lilly. As such, the bull thesis here looks pretty good. Stable Growth StoryIn the big picture, Eli Lilly has a large and growing portfolio of drugs and treatments that span a wide range of illnesses and conditions. It has broad exposure to the global healthcare market. That market is largely characterized by competitive stability, enduring demand, and mild growth. * 15 Stocks Sitting on Huge Piles of Cash Zooming in, Eli Lilly has a heavy focus on the oncology and diabetes markets, including a distinguished leadership in the diabetes market with a robust pipeline of insulin-related products. These sub-sectors of the global healthcare are likewise characterized by competitive stability, enduring demand, and mild growth.As such, so long as Eli Lilly management continues to execute on its product road-map and maintain the company's competitive positioning in the global healthcare market, this company will benefit from stable and steady revenue and profit growth.This should happen. Management has successfully navigated the healthcare market over the past decade. During that time, they've not just maintained Eli Lilly's competitive positioning. They've actually improved it. There's no reason to believe that this won't continue. Also, the company has a promising pipeline of forthcoming products. Gross margins are guided to head higher, while opex rates have room to fall.Overall, the growth story underlying Eli Lilly stock is stable and solid. That stable and solid narrative should be enough to keep the shares on a winning track. Numbers Confirm Further Upside PotentialGiven reasonable long-term growth assumptions, it is reasonable to conclude that LLY stock is slightly undervalued at the current moment. * 15 Stocks That May Be Hurt by This Year's Big IPOs The math here is very simple: U.S. healthcare spend is expected to rise by 5.5% per year over the next several years, and global healthcare spend will likely rise at a similar, if not higher, rate. Allowing for competitive slippage but also accounting for management's strong track record and the healthy product pipeline, that should flow into roughly 5% revenue growth per year for Eli Lilly. Meanwhile, margins should track higher as the company leverages acquisitions and the current pipeline -- not internal R&D -- to grow. Long term, operating margins have the potential to stabilize in the mid-30's range.Given those assumptions, I think Eli Lilly can do about $10 in EPS by 2025. Based on a historically average 20x forward multiple, that equates to a fiscal 2024 price target of $200. Discounted back by 8% per year (two points below my normal 10% discount rate to account for the yield), that results in a fiscal 2019 price target of over $135. Bottom Line on LLY StockIt increasingly appears that Eli Lilly is on a long term winning trajectory defined by stable mid-single-digit revenue growth and steady margin expansion. If so, LLY stock has the potential to hit $200 in the long run, implying healthy multi-year upside from current levels.As of this writing, Luke Lango did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks to Buy Today * 7 ETFs to Buy to Ride the Longevity Economy * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% Compare Brokers The post The Numbers Say Eli Lilly Stock Has Still More Upside For Investors appeared first on InvestorPlace.
The industry line is simple: Drugs cost a lot to develop and overcharging consumers is the only way to recoup the upfront investment. Recently, both Pfizer (NYSE:PFE) and Eli Lilly (NYSE:LLY) have been in the news for price-related issues. Frankly, I'm tired of hearing the industry's bellyaching. It's a big reason I'm not a fan of Pfizer stock or most pharmaceutical companies for that matter. * 15 Stocks That May Be Hurt by This Year's Big IPOs If you've owned Pfizer stock over the past ten years, you've done OK, achieving an annualized total return of 15%. Eli Lilly's stock over the same period has an annualized total return of 17.42%. PFE stock underperformed the S&P 500 by 188 basis point on an annual basis, while LLY stock was 56 basis points higher than the indexAny time a stock delivers a double-digit return over a long period, you've done well. Good for you.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lilly's Olive BranchThis week, Eli Lilly announced that it would introduce a generic version of its Humalog insulin injection medication at half the cost of the branded product. Same stuff. Lower price. What's not to like?That's how they want you to feel. The benevolent dictator. The problem is that it doesn't fix a fatally flawed healthcare system. It merely seeks to persuade healthcare reformists to tamp down their rhetoric so drug companies can continue to reap billions off the backs of hardworking Americans. You can fear socialism all you want, but when capitalism bankrupts people due to the high cost of drugs, you're backing the second-worst horse in a race that's likely not winnable. Senator Dick Durbin said it best when he tweeted that a half-price version of Humalog was still 73% cheaper in Canada. That's not an endorsement of Canada's healthcare system, which has its issues, but rather a severe condemnation of company's like Eli Lilly, who believe a half-priced version is part of the healthcare solution. That's like going to a retail store that's selling a product at 50% off, but still making a handsome gross profit. You walk away feeling good until you find out the product you paid $50 for actually cost $10 to produce. What's This Got to Do With Pfizer?Well, I happened to come across a CBC News piece from Feb. 15 entitled, Pfizer pushes up price of birth control used by low-income women, that highlights some price increases by the company for sexual health clinics in Southwestern Ontario. For example, its Allese and Minovral birth control pills were increased in price by 114% from CAD$7 to CAD$15 a month. Its Demulen and Synphasic birth control pills increased by 186% from CAD$7 to CAD$20 a month, and its Depo contraceptive injection increased by 40% from CAD$25 to CAD$35. The company argues that manufacturing costs have risen, necessitating the price increases.However, the price increases will hurt the people most vulnerable to this type of inflationary pressure. Those visiting the clinics are generally people who don't have a family doctor or a drug benefit plan, making the increase even harder to swallow."When these costs go up, absolutely we start to wonder whether people will be able to access these medications in the same way," said Middlesex-London Health Unit (MLHU) Associate Medical Officer of Health, Dr. Alex Summers.Situations like these demonstrate why there's a push in Canada to introduce universal pharmacare. "National pharmacare isn't just a conversation about high-cost, rare drugs needed in more extreme health conditions in our lives, but also part of our everyday preventive health," said Lauren Cipriano, assistant professor of health policy studies at the Ivey Business School. The Bottom Line on Pfizer StockWhile this particular scenario might not affect you, the fact that drug companies like Pfizer continue to initiate significant price increases without any apparent justification should concern you. So should the actions of Eli Lilly, whose recent sleight of hand might fool some of the people some of the time, but it won't fool all of them all of the time. I selected Canada Goose (NASDAQ:GOOS) as my best stock of 2019 for InvestorPlace's annual stock-picking contest despite not owning it personally. I won't, because I don't agree with its use of coyote fur on the hoods of its jackets. That's my personal choice. It doesn't have to be yours. * 7 Dividend Stocks to Buy Today The same goes for Pfizer, Eli Lilly, and the rest of the pharmaceutical companies. They're not my cup of tea, but for those who don't care about their pricing practices, they are very profitable. The choice is yours. As of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields Compare Brokers The post The Case Against Pfizer Stock and the Rest of the Industry appeared first on InvestorPlace.
Shares of major drug makers including Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Amgen Inc. (AMGN), Novartis AG (NVS) and AbbVie Inc. (ABBV), are already dramatically lagging the broader market this year.
Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.
Despite many politicians, particularly declared presidential candidates, beginning to speak out against big pharma, an FDA medical adviser does not think that anything will come out of it “because Congress is owned by pharma.”
INDIANAPOLIS, March 13, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the final results of its offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (ELAN) previously owned by Lilly, which expired at 12:00 midnight, New York City time, at the end of the day on March 8, 2019. Because the exchange offer was oversubscribed, Lilly accepted only a portion of the shares of its common stock that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Shareholders who owned fewer than 100 shares of Lilly common stock, or an "odd-lot," who validly tendered all of their shares, were not subject to proration, in accordance with the terms of the exchange offer.
German's BionTech, Europe's largest unlisted biotech firm by staff numbers, has hired banks to prepare for an initial public offering (IPO) as early as this year, people familiar with the plan told Reuters. Bank of America and JP Morgan have been retained as global coordinators for the planned listing on the U.S. Nasdaq exchange some time in the fourth quarter or in early 2020, with a stock offering worth as much as $800 million, the sources said. Biontech, which has previously said it was eyeing a future public listing, did not immediately respond to a request for comment.
Eli Lilly And Co (NYSE: LLY ) is the best-positioned among large caps, given healthy core product growth, a growing portfolio of new launches and next-gen pipeline assets, potential for significant margin ...
Eli Lilly (NYSE:LLY) announced March 4 that it was introducing a half-price generic version of Humalog, the company's insulin injection medication. Not surprisingly, LLY stock barely budged on the news, losing 1.4% on the day.Source: Paul Sableman via Flickr I don't own LLY stock. I've never contemplated holding it, and this latest move by the company ensures that I will never own Eli Lilly stock. Here's why. A Purely Financial ReasonIn 2018, Humalog generated $3.0 billion for Eli Lilly, 5% higher than a year earlier. Assuming Humalog's gross margin is 73.8% (I'm using the company's overall gross margin; it's likely higher), Eli Lilly had $2.2 billion in gross profits from this single drug.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best Stocks to Buy for the Bull Market's Anniversary Except for Trulicity, the company's bestselling diabetes drug, Humalog is the company's second-largest revenue and profit generator. In 2016, the Washington Post found that Eli Lilly increased the price of Humalog from $21 a bottle in 1996, to $255 two decades later, a 700% increase adjusting for inflation.I wish I could get a 700% increase in my annual earnings over the next 20 years, but that's unlikely to happen. Why would the company introduce a half-price version of a drug when it's a cash cow?"While this change is a step in the right direction, all of us in the health care community must do more to fix the problem of high out-of-pocket costs for Americans living with chronic conditions," CEO David Ricks said in the company's press release. "We hope our announcement is a catalyst for positive change across the U.S. health care system." That's the Official ExplanationThe truth is far murkier."By offering a generic version, it allows Lilly to fend off the criticisms," said Andrew Ching, a professor at Johns Hopkins University's Carey Business School. "By keeping the branded version, it allows them to keep charging a high price to the segment of consumers who are willing to pay more."Why on god's green earth would you pay more if you didn't have to? On the surface, it's good news for patients. "Lilly isn't the first drug maker to cut list prices on a best-seller, but it is the first to do so for a product as widely used as Humalog, and the move could have ramifications for the entire market," stated Max Nisen of the Peoria Star. "For patients, it's good news."But is it? Eli Lilly Falls Way Short of the TargetExcellent news would be the company ending full-priced Humalog sales, replaced permanently by Insulin Lispro, the name of the new generic version, but that's not going to happen. The company is going to continue to herd as many people as possible into the more expensive version, which is good news if you own LLY stock, but terrible news if you're hoping this is the start of healthcare reckoning day.It's not. The price of a vial of Humalog is close to $300. Cut that in half, and we're still talking about pulling one Benjamin Franklin and five Alexander Hamilton's out of your pocket. Here's a tweet from Senator Dick Durbin:"Eli Lilly is trying to save face by lowering prices for some to $140 for a vial of insulin that's available in Canada for as little as $38. It's time for Big Pharma to stop the PharmaFleece."If Durbin's tweet doesn't highlight just how broken America's healthcare system is, I don't know what will. The Bottom Line on LLY StockThis move by Eli Lilly is an act of desperation to save its gravy train. Do not for one minute think this is anything more than a PR stunt meant to appease the federal government so it won't introduce legislation forcing lower drug prices."If drug companies want to be part of the solution, rather than part of the problem, they should lead the way in simplifying our healthcare system so that patients can obtain affordable medicine that still provides manufacturers with a reasonable return on their investment," wrote Los Angeles Times columnist and Humalog user, David Lazarus.As someone who lives in Canada, I am so thankful that I don't have to negotiate my way through the American healthcare system. I'm not saying the Canadian system is perfect, far from it, but this move by Eli Lilly reeks of a payoff. The system is broken. And now, so is LLY stock.As of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy Under 15x Earnings * 7 Dark Horse Stocks That Deserve Your Attention in 2019 * 5 Disruptive Technologies That Are Moving Too Fast Compare Brokers The post Eli Lillyas Latest Move Proves the American Healthcare System Is Broken appeared first on InvestorPlace.
Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.
Why Eli Lilly Stock Fell YesterdayStock price movements Yesterday, Eli Lilly (LLY) closed at $123.50, 2.53% lower than its previous closing price, 65.75% higher than its 52-week low of $74.51, and 5.37% below its 52-week high of $130.51. The
Eli Lilly and Co's combination cancer treatment met the main goal of a late-stage clinical trial testing it on patients with a form of lung cancer, the drugmaker announced on Tuesday. Previously untreated patients with metastatic non-small cell lung cancer taking a combination of Lilly's Cyramza and Roche's erlotinib went longer before their disease started to worsen, study results showed. Lung cancer is the leading cause of cancer death among both men and women, and each year, more people die of lung cancer than of colon, breast, and prostate cancers combined, according to the American Cancer Society.